JP2007524412A5 - - Google Patents

Download PDF

Info

Publication number
JP2007524412A5
JP2007524412A5 JP2006551370A JP2006551370A JP2007524412A5 JP 2007524412 A5 JP2007524412 A5 JP 2007524412A5 JP 2006551370 A JP2006551370 A JP 2006551370A JP 2006551370 A JP2006551370 A JP 2006551370A JP 2007524412 A5 JP2007524412 A5 JP 2007524412A5
Authority
JP
Japan
Prior art keywords
conjugate
use according
bound
antibody
folate receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006551370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/002193 external-priority patent/WO2005069994A2/en
Publication of JP2007524412A publication Critical patent/JP2007524412A/ja
Publication of JP2007524412A5 publication Critical patent/JP2007524412A5/ja
Pending legal-status Critical Current

Links

JP2006551370A 2004-01-22 2005-01-24 葉酸コンジュゲートおよびコンプレックス Pending JP2007524412A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53839604P 2004-01-22 2004-01-22
PCT/US2005/002193 WO2005069994A2 (en) 2004-01-22 2005-01-24 Folate conjugates and complexes

Publications (2)

Publication Number Publication Date
JP2007524412A JP2007524412A (ja) 2007-08-30
JP2007524412A5 true JP2007524412A5 (cg-RX-API-DMAC7.html) 2008-03-13

Family

ID=34807186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551370A Pending JP2007524412A (ja) 2004-01-22 2005-01-24 葉酸コンジュゲートおよびコンプレックス

Country Status (6)

Country Link
US (1) US20050261170A1 (cg-RX-API-DMAC7.html)
EP (1) EP1732608A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007524412A (cg-RX-API-DMAC7.html)
AU (1) AU2005207026A1 (cg-RX-API-DMAC7.html)
CA (1) CA2553221A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005069994A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158532A0 (en) * 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
JP5175723B2 (ja) * 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
ITMC20060080A1 (it) * 2006-06-23 2007-12-24 Acom Spa Sintesi chimica di (64-rame(i)asparaginasi; [64cu(i)] asparaginasi), e utilizzo dello stesso come agente per indagini pet (positron emission tomography) e per la radioterapia.
CN1875944B (zh) * 2006-06-29 2011-01-05 中国科学院上海药物研究所 一种聚乙二醇修饰的羟基喜树碱隐形脂质纳米球及其制备方法
NO329127B1 (no) * 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) * 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
CN102231951A (zh) * 2008-11-17 2011-11-02 安龙制药公司 用于核酸传递系统的可释放的偶联物
PL226015B1 (pl) * 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
CN102526610A (zh) * 2011-12-20 2012-07-04 宋涛 一种治疗多发性大动脉炎的中药
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
KR101659855B1 (ko) 2014-05-08 2016-09-26 국립암센터 엽산을 포함하는 광역학 진단 또는 치료용 결합체 및 그를 포함하는 광역학 진단 또는 치료용 조성물
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
EP3532851A4 (en) 2016-10-06 2020-06-24 Duke University DETECTION OF CD-155, THE POLIOVIRUS RECEPTOR
WO2018075357A1 (en) * 2016-10-17 2018-04-26 Duke University PRODUCTION OF IMMUNOTOXIN D2C7-(scdsFv)-PE38KDEL
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
US12514927B2 (en) 2019-10-30 2026-01-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
CN113288871B (zh) * 2021-05-28 2022-09-16 华中科技大学 用于调控表观遗传与免疫检查点的药物组合物脂质体制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ES2191827T3 (es) * 1996-10-17 2003-09-16 Immunomedics Inc Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
ATE302217T1 (de) * 1997-05-02 2005-09-15 Us Gov Health & Human Serv Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
US6083677A (en) * 1998-04-29 2000-07-04 Eastman Kodak Company Photographic element containing yellow dye-forming photographic coupler
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7052872B1 (en) * 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US20030099629A1 (en) * 1999-03-11 2003-05-29 Immunomedics, Inc. Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
US20040043030A1 (en) * 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
AU2003283599C1 (en) * 2002-11-15 2009-06-25 Immunomedics, Inc. Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
CA2508831C (en) * 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物

Similar Documents

Publication Publication Date Title
US8846002B2 (en) Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) Anti-CD74 immunoconjugates and methods
EP1483294B1 (en) Internalizing anti-cd74 antibodies and methods of use
TWI556826B (zh) 經由樹突狀細胞凝集素樣氧化型低密度脂蛋白受體-1(lox-1)之人類抗原呈現細胞活化
JP2006500904A5 (cg-RX-API-DMAC7.html)
JP2021516976A5 (cg-RX-API-DMAC7.html)
CA3078969A1 (en) Trispecific proteins and methods of use
JP2021515566A5 (cg-RX-API-DMAC7.html)
CN110913911A (zh) 用于治疗癌症的组合疗法
JP2015502138A5 (cg-RX-API-DMAC7.html)
KR20180014050A (ko) Tigit-결합제 및 이의 용도
JP2006502698A5 (cg-RX-API-DMAC7.html)
TW200932263A (en) Antibodies that bind IL-4 and/or IL-13 and their uses
KR20170108073A (ko) Tnfrsf-결합제 및 이의 용도
JP2009538284A5 (cg-RX-API-DMAC7.html)
JP2007528372A5 (cg-RX-API-DMAC7.html)
EP1455820A2 (en) Targeted ligands
EP2806887A1 (en) Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
JP2017507922A5 (cg-RX-API-DMAC7.html)
JP2014509325A5 (cg-RX-API-DMAC7.html)
AU2020203346A1 (en) Preparations And Methods For Treating A GD2 Positive Cancer
JP7851684B2 (ja) Emt経路を遮断してがん幹細胞を克服するil8
EP4347636A2 (en) Bcma targeting trispecific proteins and methods of use
AU2005207026A1 (en) Folate conjugates and complexes
AU2018359546B2 (en) Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy